Condiciones de salud que fu ling puede ayudar a apoyar.
Both polysaccharides and triterpenoids of Poria cocos demonstrate antioxidant activity in preclinical models, elevating superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and reducing malondialdehyde (MDA). These effects are documented across hepatic, renal, and neurological injury models. In vitro antioxidant assays also confirm free radical scavenging.
Preclinical studies show Poria cocos water-soluble polysaccharides modulate anxiety-like behavior via the gut-brain axis, increasing serotonin, dopamine, and GABA levels. Pachymic acid, a key triterpene, interacts with GABA-A receptors and promotes serotonin release. Traditional TCM use for 'calming the Shen' aligns with these findings. Human clinical evidence remains limited.
Poria cocos bark extracts induced regulatory T cells (Tregs) and showed therapeutic effects in murine atopic dermatitis and food allergy models. Triterpenoid compounds from P. cocos have been used in formulas for rheumatoid arthritis and systemic lupus erythematosus. Immunomodulatory mechanisms involve Th1/Th2 balance modulation and NF-κB inhibition.
A 2022 PLOS ONE systematic review of 73 RCTs (6,489 participants) found that Fuling herbal formulae added to hypoglycaemic agents significantly reduced fasting blood glucose, 2-hour postprandial glucose, and HbA1c in type 2 diabetes. Triterpenes from P. cocos also showed anti-hyperglycaemic effects in animal models via PPAR-γ activation. Evidence is rated low-to-moderate due to risk of bias.
Poria cocos triterpenoids reduce total cholesterol and LDL while increasing HDL in dyslipidemic animal models. Polysaccharides promote reverse cholesterol transport and reduce hepatic lipid deposition. In a nephrotic syndrome rat model, P. cocos extract significantly reduced plasma total cholesterol and LDL-cholesterol.
Multiple preclinical studies demonstrate that Poria cocos ethanol extract and triterpenes suppress NF-κB signaling, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and mediators (NO, PGE2) in macrophage models. A PubMed review (2011) confirmed marked anti-inflammatory activity across multiple experimental models. Triterpenes inhibit phospholipase A2, a key enzyme in the arachidonic acid inflammatory cascade.
Multiple preclinical studies show Poria cocos polysaccharides and essential oils protect against Alzheimer's-model cognitive decline via AChE inhibition, hippocampal neuroprotection, reduction of oxidative stress, and MAPK/NF-κB pathway suppression. Pachymic acid is noted for maintaining cognitive homeostasis. Traditional TCM uses Fu Ling for amnesia, dementia, and longevity.
Preclinical rodent studies show P. cocos water extract exerts antidepressant-like effects in unpredictable chronic mild stress (UCMS) and forced swimming test (FST) models, increasing sucrose preference and reducing immobility. Mechanisms involve elevation of dopamine and serotonin in the frontal cortex and downregulation of neuroinflammation. No human clinical trials exist for depression as a primary endpoint.
A human skin study (PubMed 17026651) tested topical Poria cocos in three concentrations in a 4-day repetitive SLS-irritation model for irritant contact dermatitis (ICD), finding statistically significant anti-inflammatory activity by chromametry and transepidermal water loss. Triterpenoids also inhibited induced dermatitis in animal models via PLA2 inhibition.
Poria cocos polysaccharides have been studied for antibiotic-associated diarrhea (AAD) in preclinical models, showing restoration of gut microbiota homeostasis, increased tight junction protein ZO-1 expression, and improved intestinal mucosal barrier integrity. The Chinese Pharmacopoeia lists loose stools and diarrhea among Fu Ling's primary indications.
Multiple in vitro fecal fermentation studies demonstrate that Poria cocos polysaccharides act as prebiotics, significantly increasing Lactobacillus and Bifidobacterium while decreasing pathogenic taxa. SCFA production increases and gut microbiota diversity improves. These effects have been demonstrated using human fecal microbiota.
A clinical study (PMC10574255) in 21 adults with insomnia found that 800 mg nightly of Poria cocos ethanol extract significantly increased total sleep duration (327 to 357 min, p=0.014) and decreased sleep arousal, assessed by polysomnography. A 4-week RCT (n=70) with a P. cocos-containing combination supplement showed a 12.96% increase in total sleep duration and 59.94% improvement in PSQI scores.
Poria cocos exerts renal-protective effects via its diuretic action, anti-inflammatory properties, and antioxidant activity in preclinical kidney injury models. Carboxymethylated polysaccharides reduced TNF-α, IL-6, and IL-1β in septic acute kidney injury rats. Triterpenoids from the surface layer have demonstrated protective effects in chronic kidney disease models.
Poria cocos polysaccharides have demonstrated intestinal barrier-strengthening effects in preclinical models, upregulating tight junction protein ZO-1 in antibiotic-treated mice and preventing alcohol-induced gut leakiness. These effects are linked to reduction of intestinal inflammation and regulation of gut microbiota.
Poria cocos polysaccharides have demonstrated hepatoprotective effects in multiple preclinical models, reducing ALT, AST, and inflammatory markers in alcohol-induced and LPS/D-galactosamine-induced liver injury. P. cocos triterpenoids also promote reverse cholesterol transport and reduce liver lipid deposition. These effects are mediated via PI3K/AKT/NF-κB and antioxidant pathways.
Poria cocos polysaccharides (PCP) and essential oils have shown neuroprotective effects in Alzheimer's disease rat models, improving performance in Y-maze, Morris water maze, and novel object recognition tests. Mechanisms include acetylcholinesterase inhibition, reduction of hippocampal neuronal apoptosis, and suppression of MAPK/NF-κB signaling.
Poria cocos interacts with GABAergic, serotonergic, and dopaminergic systems in preclinical models, supporting sedative, anxiolytic, antidepressant, and neuroprotective functions. Polysaccharides protect hippocampal neurons in Alzheimer's models, and the herb appears in the Chinese Pharmacopoeia for neurological indications.
The Nutrients 2023 clinical study (n=21) using polysomnography demonstrated that 800 mg nightly Poria cocos ethanol extract significantly reduced sleep arousal, a direct measure of sleep maintenance. Animal studies also show reduced wake frequency during the sleep period following P. cocos administration.
Animal models demonstrate that P. cocos extracts reduce sleep latency and counteract caffeine-induced wakefulness, consistent with facilitation of sleep onset. The GABAergic mechanism of pachymic acid (BZD binding site activation) provides a plausible biological pathway for sleep onset facilitation.
Clinical human evidence supports Poria cocos improving overall sleep quality. An 800 mg/night clinical trial (n=21, polysomnography) showed significant increases in total sleep duration and reduced arousal. A separate 4-week RCT (n=70) reported a 59.94% improvement in PSQI scores. A meta-analysis of 13 RCTs (922 patients) also found sleep quality improvement in P. cocos-based formulas.
Preclinical studies in chronic unpredictable mild stress (UCMS) rat models demonstrate that P. cocos water extract and polysaccharides reduce stress-related behavioral deficits by downregulating neuroinflammation and normalizing monoamine levels. GABAergic modulation by pachymic acid provides a mechanistic basis for stress resilience.
Poria cocos triterpenoids and polysaccharides reduce serum triglycerides in preclinical dyslipidemia models. Triterpenoids reduce TG, LDL, and total cholesterol while increasing HDL in mice. Poria cocos oligosaccharides inhibit lipid accumulation in HFD-induced dyslipidemia, and P. cocos water extract reduced TG in a nephrotic syndrome rat model.
Poria cocos is one of the most extensively documented TCM diuretics, with the Chinese Pharmacopoeia listing edema and oliguria as primary indications. Animal studies confirm ethanol extracts of the surface layer produce marked diuresis, and the mechanism involves the AVP-V2R-AQP2 water channel axis. Clinical human data are limited.
Fu Ling is listed in the Chinese Pharmacopoeia for 'Spleen deficiency' with symptoms including abdominal pressure, bloating, loose stools, and diarrhea. Classical TCM formulas like Si Jun Zi Tang and Wu Ling San incorporate Fu Ling to address abdominal complaints linked to fluid accumulation and digestive weakness.
In TCM, Fu Ling is classified as a 'spirit-calming' (An Shen) herb, used for over 2,500 years to promote mental equilibrium and ease restlessness. The Chinese Pharmacopoeia lists it for restlessness and palpitations. Preclinical evidence supports GABAergic and serotonergic mechanisms underlying this property.
Fu Ling is classified in TCM as a Qi tonic and has been used for centuries for fatigue, weakness, and recovery from debilitating illness. It is listed among historical uses for 'recovery from long illness' and physical weariness. The Chinese Pharmacopoeia Shennong Bencao Jing classifies it as a superior herb for promoting vitality.
Classical TCM texts and pharmacological reviews document Fu Ling as a treatment for 'chronic gastritis, acute gastroenteric catarrh, and gastric atony.' The pachymic acid constituent has been noted for established effectiveness in chronic gastritis. TCM formulas incorporating Fu Ling are used for spleen-stomach disharmony underlying gastritis patterns.
Fu Ling is used in TCM for patterns corresponding to IBS symptoms — loose stools, diarrhea, abdominal bloating, and digestive weakness due to Spleen deficiency. Classical formulas like Si Jun Zi Tang and Shen Ling Bai Zhu San (specifically for Spleen deficiency with diarrhea) include Fu Ling as a core ingredient.
The Chinese Pharmacopoeia lists Fu Ling for 'phlegm' and 'productive cough,' and classical TCM texts describe it as resolving 'dampness and phlegm' accumulation. It is used in formulas such as Er Chen Tang for phlegm-related conditions. Scientific evidence for this specific indication is limited to its traditional context.
The inner layer of Poria cocos (Fu Ling) is traditionally used for nausea, emesis, and gastric atony in TCM and Japanese Kampo medicine. Classical indications recorded in the Chinese Pharmacopoeia and historical texts document its use for these gastrointestinal symptoms. Scientific evidence for this specific endpoint is absent.
Fu Ling has been used for over 2,500 years in TCM for urinary retention, oliguria, and urinary infections, documented in the Chinese Pharmacopoeia for 'edema and oliguria.' Classical formulas such as Wu Ling San address fluid retention and urinary dysfunction. Diuretic effects have been confirmed in animal studies but not human clinical trials.
The Chinese Pharmacopoeia explicitly lists dizziness (vertigo) among Fu Ling's primary indications, particularly dizziness arising from fluid accumulation and phlegm obstruction. Classical TCM formulas like Wu Ling San address fluid-related dizziness. No modern clinical trials support this indication.